OBJECTIVE: To evaluate the feasibility of on-board diffusion-weighted imaging (DWI) with an integrated low-field MRI radiotherapy system to assess responses to neoadjuvant chemoradiation (NAC) in rectal cancer. METHODS: A spin echo-based planar imaging diffusion sequence on a 0.35-T MRI radiotherapy system was acquired over the course of NAC. The apparent diffusion coefficients (ADCs) from the tumour regions of interest (ROIs) were calculated. A functional diffusion map (fDM) was created showing a pixelwise ADC analysis of the ROI over the course of treatment. Surgical pathology was correlated with ADC data. RESULTS: Consecutive patients treated on a 0.35-T MRI radiotherapy system were evaluated. Patient A had the worst pathological response to NAC with a tumour regression score of 1 and was the only patient with a negative slope in the change of ADC values over the entire course of NAC, and during both the first and second half of NAC. The fDM from the first half of NAC for Patient A showed discrete dark areas in the tumour ROI, reflecting subregions with decreasing ADC values during NAC. Patient C had the most favourable pathological response to NAC with a Grade 3 response and was the only patient who had an increase in the slope in the change of ADC values from the first to the second half of NAC. CONCLUSION: DWI using a low-field MRI radiotherapy system for evaluating the responses to NAC is feasible. Advances in knowledge: ADC values obtained using a 0.35-T MRI radiotherapy system over the course of NAC for rectal cancer correlate with pathological responses.
OBJECTIVE: To evaluate the feasibility of on-board diffusion-weighted imaging (DWI) with an integrated low-field MRI radiotherapy system to assess responses to neoadjuvant chemoradiation (NAC) in rectal cancer. METHODS: A spin echo-based planar imaging diffusion sequence on a 0.35-T MRI radiotherapy system was acquired over the course of NAC. The apparent diffusion coefficients (ADCs) from the tumour regions of interest (ROIs) were calculated. A functional diffusion map (fDM) was created showing a pixelwise ADC analysis of the ROI over the course of treatment. Surgical pathology was correlated with ADC data. RESULTS: Consecutive patients treated on a 0.35-T MRI radiotherapy system were evaluated. Patient A had the worst pathological response to NAC with a tumour regression score of 1 and was the only patient with a negative slope in the change of ADC values over the entire course of NAC, and during both the first and second half of NAC. The fDM from the first half of NAC for Patient A showed discrete dark areas in the tumour ROI, reflecting subregions with decreasing ADC values during NAC. Patient C had the most favourable pathological response to NAC with a Grade 3 response and was the only patient who had an increase in the slope in the change of ADC values from the first to the second half of NAC. CONCLUSION: DWI using a low-field MRI radiotherapy system for evaluating the responses to NAC is feasible. Advances in knowledge: ADC values obtained using a 0.35-T MRI radiotherapy system over the course of NAC for rectal cancer correlate with pathological responses.
Authors: Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2011-04-28 Impact factor: 12.531
Authors: Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: Yingli Yang; Minsong Cao; Ke Sheng; Yu Gao; Allen Chen; Mitch Kamrava; Percy Lee; Nzhde Agazaryan; James Lamb; David Thomas; Daniel Low; Peng Hu Journal: Med Phys Date: 2016-03 Impact factor: 4.071
Authors: Doenja M J Lambregts; Sheng-Xiang Rao; Sander Sassen; Milou H Martens; Luc A Heijnen; Jeroen Buijsen; Meindert Sosef; Geerard L Beets; Roy A Vliegen; Regina G H Beets-Tan Journal: Ann Surg Date: 2015-12 Impact factor: 12.969
Authors: Julio Garcia-Aguilar; Lindsay A Renfro; Oliver S Chow; Qian Shi; Xiomara W Carrero; Patricio B Lynn; Charles R Thomas; Emily Chan; Peter A Cataldo; Jorge E Marcet; David S Medich; Craig S Johnson; Samuel C Oommen; Bruce G Wolff; Alessio Pigazzi; Shane M McNevin; Roger K Pons; Ronald Bleday Journal: Lancet Oncol Date: 2015-10-22 Impact factor: 41.316
Authors: L E Henke; J A Contreras; O L Green; B Cai; H Kim; M C Roach; J R Olsen; B Fischer-Valuck; D F Mullen; R Kashani; M A Thomas; J Huang; I Zoberi; D Yang; V Rodriguez; J D Bradley; C G Robinson; P Parikh; S Mutic; J Michalski Journal: Clin Oncol (R Coll Radiol) Date: 2018-09-07 Impact factor: 4.126
Authors: William A Hall; Eric S Paulson; Uulke A van der Heide; Clifton D Fuller; B W Raaymakers; Jan J W Lagendijk; X Allen Li; David A Jaffray; Laura A Dawson; Beth Erickson; Marcel Verheij; Kevin J Harrington; Arjun Sahgal; Percy Lee; Parag J Parikh; Michael F Bassetti; Clifford G Robinson; Bruce D Minsky; Ananya Choudhury; Robert J H A Tersteeg; Christopher J Schultz Journal: Eur J Cancer Date: 2019-10-12 Impact factor: 9.162
Authors: Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi Journal: Radiat Oncol Date: 2020-05-05 Impact factor: 3.481
Authors: Luca Boldrini; Elisa Placidi; Nicola Dinapoli; Luigi Azario; Francesco Cellini; Mariangela Massaccesi; Silvia Chiesa; Maria Antonietta Gambacorta; Gian Carlo Mattiucci; Danila Piccari; Stefania Teodoli; Marco De Spirito; Vincenzo Valentini Journal: Tech Innov Patient Support Radiat Oncol Date: 2018-03-31
Authors: Leila T Tchelebi; Paul B Romesser; Sebastian Feuerlein; Sarah Hoffe; Kujtim Latifi; Seth Felder; Michael D Chuong Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302